Successfully Met Goals Outlined in MassBio's Diversity, Equity, and Inclusion (DE&I) Industry Pledge -New Disclosures of Company's Impact on Planet-Including Multiyear Data on Scope 1, Scope 2, and Select
Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPa and sAPPß in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date Encouraging Clinical Safety and
Ms. Nakamura brings over 30 years of leadership in commercializing therapies internationally, including most recently as SVP, Head of Asia at Alnylam Pharmaceuticals
Joins Amylyx as a key leader. | April 20, 2023
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) announced Loss for fourth quarter that decreased from the same period last year and beat the Street estimates.The company's bottom line